These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 28704936)

  • 1. Effects of a New Nutraceutical Formulation (Berberine, Red Yeast Rice and Chitosan) on Non-HDL Cholesterol Levels in Individuals with Dyslipidemia: Results from a Randomized, Double Blind, Placebo-Controlled Study.
    Spigoni V; Aldigeri R; Antonini M; Micheli MM; Fantuzzi F; Fratter A; Pellizzato M; Derlindati E; Zavaroni I; Bonadonna RC; Dei Cas A
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28704936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nutraceutical approach for the management of cardiovascular risk - a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: results from a randomized, double-blind, placebo-controlled study.
    Ruscica M; Pavanello C; Gandini S; Macchi C; Botta M; Dall'Orto D; Del Puppo M; Bertolotti M; Bosisio R; Mombelli G; Sirtori CR; Calabresi L; Magni P
    Nutr J; 2019 Feb; 18(1):13. PubMed ID: 30795775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
    Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP
    Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with Armolipid Plus.
    Ruscica M; Gomaraschi M; Mombelli G; Macchi C; Bosisio R; Pazzucconi F; Pavanello C; Calabresi L; Arnoldi A; Sirtori CR; Magni P
    J Clin Lipidol; 2014; 8(1):61-8. PubMed ID: 24528686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of a nutraceutical combination on lipid metabolism in patients with metabolic syndrome: a multicenter, double blind, randomized, placebo controlled trial.
    Galletti F; Fazio V; Gentile M; Schillaci G; Pucci G; Battista F; Mercurio V; Bosso G; Bonaduce D; Brambilla N; Vitalini C; D'Amato M; Giacovelli G
    Lipids Health Dis; 2019 Mar; 18(1):66. PubMed ID: 30885221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.
    Blais JE; Huang X; Zhao JV
    Drugs; 2023 Apr; 83(5):403-427. PubMed ID: 36941490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized, Double-Blinded, Placebo-Controlled, Clinical Study of the Effects of a Nutraceutical Combination (LEVELIP DUO
    Cicero AFG; D'Addato S; Borghi C
    Nutrients; 2020 Oct; 12(10):. PubMed ID: 33066334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testing the Short-Term Efficacy of a Lipid-Lowering Nutraceutical in the Setting of Clinical Practice: A Multicenter Study.
    Cicero AF; Derosa G; Pisciotta L; Barbagallo C;
    J Med Food; 2015 Nov; 18(11):1270-3. PubMed ID: 26274827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ESSENS dyslipidemia: A placebo-controlled, randomized study of a nutritional supplement containing red yeast rice in subjects with newly diagnosed dyslipidemia.
    Kasliwal RR; Bansal M; Gupta R; Shah S; Dani S; Oomman A; Pai V; Prasad GM; Singhvi S; Patel J; Sivam S; Trehan N
    Nutrition; 2016; 32(7-8):767-76. PubMed ID: 27143594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients.
    Marazzi G; Cacciotti L; Pelliccia F; Iaia L; Volterrani M; Caminiti G; Sposato B; Massaro R; Grieco F; Rosano G
    Adv Ther; 2011 Dec; 28(12):1105-13. PubMed ID: 22113535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Nutraceutical Combination of Monacolin K, Berberine, and Silymarin on Lipid Profile and PCSK9 Plasma Level in a Cohort of Hypercholesterolemic Patients.
    Formisano E; Pasta A; Cremonini AL; Favari E; Ronca A; Carbone F; Semino T; Di Pierro F; Sukkar SG; Pisciotta L
    J Med Food; 2020 Jun; 23(6):658-666. PubMed ID: 31663806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proprotein convertase subtilisin/kexin type 9 inhibitors treatment in dyslipidemic patients: a real world prescription.
    Derosa G; Maffioli P; D'Angelo A; Girola A; Colombo E; Fiorenza AM; Macias JJC; Sanchez CL; Raddino R; Pasini GF; Triggiani M; Maresca AM; Tandurella N; Guasti L
    J Cardiovasc Med (Hagerstown); 2022 Feb; 23(2):91-97. PubMed ID: 34690259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study.
    Brouwers MC; Troutt JS; van Greevenbroek MM; Ferreira I; Feskens EJ; van der Kallen CJ; Schaper NC; Schalkwijk CG; Konrad RJ; Stehouwer CD
    Atherosclerosis; 2011 Jul; 217(1):263-7. PubMed ID: 21497351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of a nutraceutical combination on plasma lipids and glucose: A systematic review and meta-analysis of randomized controlled trials.
    Pirro M; Mannarino MR; Bianconi V; Simental-Mendía LE; Bagaglia F; Mannarino E; Sahebkar A
    Pharmacol Res; 2016 Aug; 110():76-88. PubMed ID: 27157250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NUtraceutical TReatment for hYpercholesterolemia in HIV-infected patients: The NU-TRY(HIV) randomized cross-over trial.
    Pirro M; Francisci D; Bianconi V; Schiaroli E; Mannarino MR; Barsotti F; Spinozzi A; Bagaglia F; Sahebkar A; Baldelli F
    Atherosclerosis; 2019 Jan; 280():51-57. PubMed ID: 30471555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: results from a crossover study.
    Noguchi T; Kobayashi J; Yagi K; Nohara A; Yamaaki N; Sugihara M; Ito N; Oka R; Kawashiri MA; Tada H; Takata M; Inazu A; Yamagishi M; Mabuchi H
    Atherosclerosis; 2011 Jul; 217(1):165-70. PubMed ID: 21411093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endotelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trial.
    Trimarco V; Izzo R; Stabile E; Rozza F; Santoro M; Manzi MV; Serino F; Schiattarella GG; Esposito G; Trimarco B
    High Blood Press Cardiovasc Prev; 2015 Jun; 22(2):149-54. PubMed ID: 25870124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
    Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L
    Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
    Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
    J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.